Compare CVS Health Corp (CVS) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Global X Uranium ETF — how do they compare? CVS Health Corp trades at $94.92 (market cap $119.58B), while Global X Uranium ETF trades at $45.25. The key difference: CVS Health Corp pays a 2.84% dividend while Global X Uranium ETF pays none, and CVS Health Corp is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| CVS | URA | |
|---|---|---|
Market Cap | $119.58B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $110.60 | $61.81 |
52-Week Low | $65.51 | $36.45 |
Enterprise Value | $181.93B | — |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $94.70, down 1.01% with strong technical support at $93-$91 levels. The company reported robust Q2 2026 earnings of $2.58 per share, beating estimates by 38%, while raising full-year guidance. Revenue growth accelerated to 7.3% year-over-year, driven by Aetna's recovery and retail strength. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $115.90 price target representing 22% upside potential.
CVS presents compelling value with a 0.29 P/S ratio and positive earnings momentum, though net margins remain thin at 1.18%. Key risks include 2027 PBM pressure and healthcare regulatory changes. The stock's current technical weakness near support levels offers potential entry point for long-term investors seeking exposure to integrated healthcare services.
URA, the Global X Uranium ETF, trades at $45.34, up 2.16% today with a bullish technical signal from moving averages. The ETF benefits from strong nuclear energy tailwinds including $17.5 billion in federal funding and growing AI power demand. Recent index additions like Terra Innovatum and Eagle Nuclear Energy expand the fund's exposure to nuclear infrastructure companies.
The uranium sector faces near-term volatility but long-term structural growth drivers remain intact. Key risks include policy uncertainty and uranium price fluctuations, while opportunities stem from nuclear energy's role in meeting AI power demands and global decarbonization goals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
